INTERVIEW: Ramona Sequeira Rolls Out Takeda's American Dream
Since Ramona Sequeira was made president of Takeda's US business a year ago, she has set out a new strategy that she hopes will add to the turnaround of the Japanese major after a difficult patch in its history.
You may also be interested in...
Takeda Pharmaceutical Co. Ltd. has closed out its "turnaround year" on target, meeting guidance for fiscal 2015. The company has been undergoing a reorganization to pull it through intense generic competition and CEO Christophe Weber took the year-end opportunity to outline how the strategy was playing out for Japanese pharma.
A fundamental restructuring of Takeda Pharmaceutical's vaccines operations will see the closure of three sites in the US as it consolidates operations in this market in the Boston area as part of a revised global network for the unit.
Following the massive financial hit of the recent Actos settlement, Takeda appears set to return to profitable growth this fiscal year after a 12-month period during which its new CEO says the Japanese firm "hit bottom."